欧洲限制性胜胜肽药物市场 – 分析与预测（2024-2040）

欧洲限制性胜胜肽药物市场规模预计到2026年将达到6,000万美元，到2040年将达到77.2亿美元，2026-2040年预测期间复合年增长率为41.55%。

在创新的限制性胜肽管道的推动下，限制性胜肽药物市场有望显着成长，这些管道现在不仅仅针对受体。化学技术的进步、合成胜胜肽在治疗方面的成功以及各种疾病的可负担性也有助于预测期内的预期成长。

欧洲限制性胜胜肽药物市场预计在未来几年将显着成长。这一市场扩张的主要驱动力之一是该地区强大的製药业，其特点是研发、创新和强大的法规结构。欧洲製药公司利用胜肽化学领域的最尖端科技和专业知识，一直处于开发限制性胜肽药物的最前线。

此外，欧洲对新型治疗方法的需求不断增长，特别是在治疗癌症、自体免疫疾病和代谢疾病等各种疾病方面。限制性胜肽因其特异性、提高功效和安全性的潜力而提供了一种有前景的解决方案。

此外，在欧洲，学术界、研究机构和製药公司之间的合作正在加速限制性胜肽疗法的发现和开发。这样的协作生态系统促进创新，并将欧洲定位为限制性胜胜肽药物市场的关键进入市场。

本报告考察了欧洲限制性胜胜肽药物市场，提供了市场概述、按国家和公司分類的趋势以及进入市场的公司概况。

目录

执行摘要

第一章 定义

第二章 研究范围

第三章调查方法

第四章市场概况

• 介绍
  • 限制性胜肽的结构和设计
  • 限制性胜肽的类型
• 抑制因素胜肽的进化
• 限制性胜肽药物的开发
• 潜在的治疗领域
• 价值链 - 主要相关人员
• 主要产业趋势（按地区）
• 按行政途径分類的主要行业趋势
• 主要行业趋势 - 技术进步
• 当前市场规模和成长潜力（十亿美元），2024-2040 年
• COVID-19对限制性胜肽药物市场的影响
  • 对限制性胜肽药物公司的影响
  • 临床试验的暂停与恢復

第五章 欧洲

• 限制性胜胜肽药物市场（按国家），十亿美元，2024-2031
  • 欧洲

第六章 公司简介

• Bicycle Therapeutics plc
• Spexis AG
• Santhera Pharmaceuticals
• Union Chimique Belge SA（UCB）
• Biosynth（Pepscan）

“The Europe Constrained Peptide Drugs Market Expected to Reach $7.72 Billion by 2040.”

Introduction to Europe constrained peptide drugs market

The market size is anticipated to be $0.06 billion in 2026 and is expected to reach $7.72 billion by 2040, growing at a CAGR of 41.55% during the forecast period 2026-2040. The constrained peptide drugs market is expected to experience significant growth, driven by innovative constrained peptide pipelines that now target more than just receptors. Advances in chemical technologies, the success of synthetic peptides in therapeutics, and their affordability across various diseases are also contributing to the projected growth in the forecast period.

Market Introduction

The Europe constrained peptide drugs market is poised for substantial growth in the coming years. One of the key drivers of this expansion is the region's robust pharmaceutical industry, characterized by a focus on research and development, innovation, and a strong regulatory framework. European pharmaceutical companies have been at the forefront of developing constrained peptide drugs, leveraging cutting-edge technologies and expertise in peptide chemistry.

Additionally, Europe has witnessed a growing demand for novel therapeutic approaches, particularly in the treatment of various diseases such as cancer, autoimmune disorders, and metabolic conditions. Constrained peptides offer a promising solution due to their specificity and potential for enhanced efficacy and safety profiles.

Furthermore, collaborative efforts between academia, research institutions, and pharmaceutical companies in Europe have accelerated the discovery and development of constrained peptide-based therapeutics. This collaborative ecosystem fosters innovation and positions Europe as a significant player in the constrained peptide drugs market.

Market Segmentation

Segmentation 1: by Country

• Germany
• U.K.
• France
• Italy
• Spain

Segmentation 2: by Company

• Bicycle Therapeutics plc
• Spexis AG
• Santhera Pharmaceuticals
• Union Chimique Belge S.A. (UCB)
• Biosynth (Pepscan)
• Zealand Pharma

How can this report add value to an organization?

Workflow/Innovation Strategy: Over the past decade, peptide drug discovery and development has witnessed a renaissance and scientific thrust as the industry has come to acknowledge the capability of peptide therapeutics in addressing unmet medical needs and the potential of this class of molecules to become a significant accompaniment or even favored alternative treatment to biologics and small molecules.

Peptide therapeutics have demonstrated a novel and selective yet safe mode of action for a wide range of indications. The existing and future development of constrained peptide drugs will continue to burgeon upon the strengths of constrained peptides and innovative technologies employed in the discovery and development, including peptide drug conjugates, multifunctional peptides, and cell-penetrating peptides. Furthermore, limitations associated with presently available peptides have resulted in an urgent need for new design, administration, and synthesis in peptide therapeutics, thereby leading to advancements in the development of constrained peptides.

Growth/Marketing Strategy: Constrained peptides provide noteworthy advantages over linear peptides. An increase in interest in constrained peptides due to their properties led to advancements in peptide synthesis technologies.

Competitive Strategy: Key players in the Europe constrained peptide drugs market have been analyzed and profiled in the study, including manufacturers involved in new product development, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe constrained peptide drugs market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Table of Contents

Executive Summary

1. Definition

• 1.1. Inclusion and Exclusion Criteria

2. Research Scope

• 2.1. Key Questions Answered in the Report

3. Research Methodology

• 3.1. Constrained Peptides: Research Methodology
• 3.2. Primary Data Sources
• 3.3. Secondary Data Sources
• 3.4. Market Estimation Model
• 3.5. Criteria for Company Profiling

4. Markets Overview

• 4.1. Introduction
  • 4.1.1. Structure and Design of Constrained Peptides
  • 4.1.2. Types of Constrained Peptides
• 4.2. Evolution of Constrained Peptides
• 4.3. Development of Constrained Peptides as Drugs
• 4.4. Potential Therapy Areas
• 4.5. Value Chain-Key Stakeholders
• 4.6. Key Industry Trends (by Region)
• 4.7. Key Industry Trends by Route of Administration
• 4.8. Key Industry Trends-Technological Advancements
• 4.9. Current Market Size and Growth Potential, $Billion, 2024-2040
• 4.1. COVID-19 Impact on Constrained Peptides Drugs Market
  • 4.10.1. Impact on Constrained Peptide Drugs Companies
  • 4.10.2. Clinical Trial Disruptions and Resumptions

5. Europe

• 5.1. Constrained Peptide Drugs Market (by Country), $Billion, 2024-2031
  • 5.1.1. Europe
    • 5.1.1.1. U.K.
    • 5.1.1.2. Germany
    • 5.1.1.3. France
    • 5.1.1.4. Italy
    • 5.1.1.5. Spain

6. Company Profiles

• 6.1. Overview
• 6.2. Bicycle Therapeutics plc
  • 6.2.1. Company Overview
  • 6.2.2. Role of Bicycle Therapeutics plc in the Constrained Peptide Drugs Market
  • 6.2.1. Current Status and Policies for Investigational Drugs
  • 6.2.2. Key Competitors of the Company
  • 6.2.3. Financials
  • 6.2.4. Key Insights about the Financial Health of the Company
  • 6.2.5. Corporate Strategies
    • 6.2.5.1. Synergistic Activities
    • 6.2.5.2. Funding
  • 6.2.6. Business Strategies
    • 6.2.6.1. Clinical Developments
    • 6.2.6.2. Regulatory and Legal
  • 6.2.7. Analyst Perspective
• 6.3. Spexis AG
  • 6.3.1. Company Overview
  • 6.3.2. Role of Spexis AG in the Constrained Peptide Drugs Market
  • 6.3.3. Current Status and Policies for Investigational Drugs
  • 6.3.4. Key Competitors of the Company
  • 6.3.5. Financials
  • 6.3.6. Key Insights about the Financial Health of the Company
  • 6.3.7. Corporate Strategies
    • 6.3.7.1. Funding
    • 6.3.7.2. Mergers and Acquisitions
    • 6.3.7.3. Synergistic activities
  • 6.3.8. Business Strategies
    • 6.3.8.1. Regulatory and Legal
  • 6.3.9. Analyst Perspective
• 6.4. Santhera Pharmaceuticals
  • 6.4.1. Company Overview
  • 6.4.2. Role of Santhera Pharmaceuticals in the Constrained Peptide Drugs Market
  • 6.4.3. Current Status and Policies for Investigational Drugs
  • 6.4.4. Key Competitors of the Company
  • 6.4.5. Financials
  • 6.4.6. Corporate Strategies
    • 6.4.6.1. Funding
  • 6.4.7. Business Strategies
    • 6.4.7.1. Clinical Developments
  • 6.4.8. Analyst Perspective
• 6.5. Union Chimique Belge S.A. (UCB)
  • 6.5.1. Company Overview
  • 6.5.2. Role of Union Chimique Belge S.A. (UCB) in the Constrained Peptide Drugs Market
  • 6.5.3. Current Status and Policies for Investigational Drugs
  • 6.5.4. Key Competitors of the Company
  • 6.5.5. Financials
  • 6.5.6. Key Insights about the Financial Health of the Company
  • 6.5.7. Corporate Strategies
    • 6.5.7.1. Mergers and Acquisitions
  • 6.5.8. Business Strategies
    • 6.5.8.1. Clinical Developments
    • 6.5.8.2. Regulatory and legal
  • 6.5.9. Analyst Perspective
• 6.6. Biosynth (Pepscan)
  • 6.6.1. Company Overview
  • 6.6.2. Role of Biosynth (Pepscan) in the Constrained Peptide Drugs Market
  • 6.6.3. Key Competitors of the Company
  • 6.6.4. Corporate Strategies
    • 6.6.4.1. License
  • 6.6.5. Business Strategies
    • 6.6.5.1. Product Launch
  • 6.6.6. Analyst Perspective
  • 6.6.7. Zealand Pharma
    • 6.6.7.1. ZP10000 (Preclinical)
      • 6.6.7.1.1. Product Profile

List of Figures

• Figure 1: Europe Total Number of Drugs Approved by the U.S. FDA, 2016-2021
• Figure 2: Europe Constrained Peptide Drugs Market, $Billion, 2024-2031
• Figure 3: Europe Constrained Peptide Drugs Market, $Billion, 2032-2040
• Figure 4: Europe Constrained Peptide Drugs: Impact Analysis
• Figure 5: Constrained Peptide Drugs Market (by Region), $Billion, 2024-2040
• Figure 6: Constrained Peptide Drugs Methodology
• Figure 7: Primary Research Methodology
• Figure 8: Epidemiology-Based Approach
• Figure 9: Inducing Conformational Effects
• Figure 10: Two Main Types of Constraints
• Figure 11: Methodology for Restricting Conformation in Peptides
• Figure 12: Types of Constrained Peptides
• Figure 13: Key Milestones in the Evolution of Constrained Peptides
• Figure 14: Major Factors Affecting Constrained Peptide Development
• Figure 15: Value Chain Analysis- Key Stakeholders
• Figure 16: Constrained Peptide Drugs Market (by Region), $Billion, 2024-2031
• Figure 17: Constrained Peptide Drugs Market (by Region), $Billion, 2032-2040
• Figure 18: Europe Constrained Peptide Drugs Market, $Billion, 2024-2031
• Figure 19: Europe Constrained Peptide Drugs Market, $Billion, 2032-2040
• Figure 20: Constrained Peptide Drugs Market (by Region)
• Figure 21: Constrained Peptide Drugs Market (by Region), $Billion, 2024-2040
• Figure 22: Europe Constrained Peptide Drugs Market, $Billion, 2024-2031
• Figure 23: Europe Constrained Peptide Drugs Market, $Billion, 2032-2040
• Figure 24: Europe: Market Dynamics
• Figure 25: Europe Constrained Peptide Drugs Market (by Country), $Billion, 2025 and 2040
• Figure 26: U.K. Constrained Peptide Drugs Market, $Billion, 2024-2031
• Figure 27: U.K. Constrained Peptide Drugs Market, $Billion, 2032-2040
• Figure 28: Germany Constrained Peptide Drugs Market, $Billion, 2024-2031
• Figure 29: Germany Constrained Peptide Drugs Market, $Billion, 2032-2040
• Figure 30: France Constrained Peptide Drugs Market, $Billion, 2024-2031
• Figure 31: France Constrained Peptide Drugs Market, $Billion, 2032-2040
• Figure 32: Italy Constrained Peptide Drugs Market, $Billion, 2024-2031
• Figure 33: Italy Constrained Peptide Drugs Market, $Billion, 2032-2040
• Figure 34: Spain Constrained Peptide Drugs Market, $Billion, 2024-2031
• Figure 35: Spain Constrained Peptide Drugs Market, $Billion, 2032-2040
• Figure 36: Total Number of Companies Profiled
• Figure 37: Bicycle Therapeutics plc: Product Portfolio
• Figure 38: Bicycle Therapeutics plc: Overall Financials, $Million, 2019-2021
• Figure 39: Bicycle Therapeutics plc: Revenue (by Region), $Million, 2019-2021
• Figure 40: Bicycle Therapeutics plc: R&D Expenditure, $Million, 2019-2021
• Figure 41: Spexis AG: Product Portfolio
• Figure 42: Spexis AG: Overall Financials, $Million, 2019-2021
• Figure 43: Spexis AG: R&D Expenditure, $Million, 2019-2021
• Figure 44: Santhera Pharmaceuticals: Product Portfolio
• Figure 45: Santhera Pharmaceuticals: Overall Financials, $Million, 2019-2021
• Figure 46: Union Chimique Belge S.A. (UCB): Product Portfolio
• Figure 47: Union Chimique Belge S.A. (UCB): Overall Financials, $Million, 2019-2021
• Figure 48: Union Chimique Belge S.A. (UCB): R&D Expenditure, $Million, 2019-2021
• Figure 49: Biosynth (Pepscan): Product Portfolio

List of Tables

• Table 1: Potential Indications of Constrained Peptide Drugs
• Table 2: Potential Therapy Areas of Constrained Peptide Drugs
• Table 3: Route of Administration of Constrained Peptide Drugs
• Table 4: Impact of COVID-19 on Constrained Peptide Drug Companies